Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RVX-sCPD9
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration
Rocketvax Collaborates with NIH for Clinical Trial of RVX-sCPD9 Candidate
Details : Through the collaboration, Rocketvax aims to focus on developing the next-generation live-attenuated viral vaccine RVX-sCPD9, which is being evaluated for the treatment of COVID-19.
Product Name : RVX-sCPD9
Product Type : Vaccine
Upfront Cash : Undisclosed
June 13, 2024
Lead Product(s) : RVX-sCPD9
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration